Every Diagnosis of Cancer Should Come with One of These, Says Cancer Expert

Economic Disparities a Growing Concern for Cancer Diagnosis and Treatment

Sbarro Health Research Organization President Re-Elected to Board of Italian American Foundation

Thorough Genotyping and Repurposed Drugs Key to Treating Small-Cell Lung Cancer, says Cancer Expert

Tomato Extract Fights Stomach Cancer, Ripe for Further Study

Adding Radiation Treatments to Inoperable Lung Cancer Increases Survival by up to One Year

Research Reveals Gene Differences in Mouse Model Versus Humans

Clinical Data Confirms Efficacy of Pre-Surgery Chemo in Triple-Negative Breast Cancer

Does Radiology Contrast Medium Matter? To Fragile Cancer Patients, Yes

Targeting Cell Cycle Reactivation Caused by Inflammation May Provide the Way to Prevent Neuron Death in Alzheimer’s Disease

Italian-American Researchers Present Mediterranean Diet, Health, and Longevity at Annual Medical Conference

New Cancer Therapies Earn Sbarro Health Research Organization President Antonio Giordano 2017 CORE Prize for Oncology

From Medical Discovery to Food and Fine Arts, Italian-American Contributions Celebrated at Annual Foundation Conference

Xylella: a conscience, not a science problem

Detecting Pompe Disease with More Accuracy Key to Urgent Intervention

Fluctuations of Sex Steroid Hormone Could be Culprit in Age-Related Macular Degeneration

Diverse Role of CDK9 Gene in Cell Regulation Continues to Reveal Cancer Treatment Targets 25 Years After Discovery

Repurposed Parasite Drug New Weapon Against Mesothelioma

Understanding Cancer Heterogeneity Could Further Reduce Chemo Use, Says Expert

Decoy Damaged DNA Discovers New Gene Repair Protein

Enzyme Inhibition May Lead to New Melanoma Therapy, Say Researchers at Fox Chase with Support from Sbarro Institute

Brain Cancer Drug Reactivates Body's Natural Defenses

Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review

Exploiting RB1 Predictive Value for Cancer Therapy in the Clinical Setting: Lost in Translation

New Natural Therapeutic Agent to Fight Diabetic Nephropathy

In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Giordano’s discovery of the tumor suppressor gene pRb2. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Dr. Giordano was a professor. When Dr. Giordano moved to Temple University in 2002, he and twenty fellow scientists forged a new, three-year alliance with Temple University in Philadelphia, Pennsylvania. Under the new arrangement, the original Sbarro Institute was renamed the Sbarro Health Research Organization, Inc. (SHRO), which includes the Sbarro Institute for Cancer Research and Molecular Medicine at Temple and the SHRO-affiliated laboratory at the University of Siena in Siena, Italy. Under a 2005 agreement, the Sbarro Institute for Cancer Research and Molecular Medicine received continued funding from Temple and expanded its program to include work on the relationship between obesity and cancer and instituted a new program on molecular therapeutics to explore how molecular genetic research can be applied to patient therapies and diagnostics. SHRO relies on grants and private donations to fund important biomedical research.

Mobile No : 215-204-9520

Email : president@shro.org